image credit- shutterstock
Japan-headquartered pharmaceutical firm Eisai has entered into an exclusive license agreement with a subsidiary of SciClone Pharmaceuticals (Holdings) Limited (Shanghai, China) for the development and distribution of tasurgratinib succinate (E7090, Japan brand name: TASFYGO) in the Greater China region (Mainland China, Hong Kong, Macau, and Taiwan).
Eisai retains global rights outside these regions and will continue manufacturing and marketing in Japan, where tasurgratinib was launched in November 2024.
Under the agreement, Eisai will receive an upfront payment, milestone payments tied to development progress and regulatory approvals, as well as sales-based milestone payments and royalties upon commercialization.
Tasurgratinib, an orally available tyrosine kinase inhibitor, selectively inhibits FGFR1, FGFR2, and FGFR3. It is approved in Japan for the treatment of unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that have progressed after chemotherapy. A Phase I clinical trial is also ongoing in Japan for estrogen receptor-positive and HER2-negative breast cancer.
SciClone, a leading biopharmaceutical company with a strong presence in Greater China, will leverage its expertise to accelerate tasurgratinib’s availability in the licensed regions. Eisai anticipates this collaboration will expand patient access and maximize the therapeutic potential of tasurgratinib in the region.
